Dirk Thye - 16 Jan 2024 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Dirk Thye
Issuer symbol
QNCX
Transactions as of
16 Jan 2024
Net transactions value
+$190,791
Form type
4
Filing time
17 Jan 2024, 16:48:28 UTC
Previous filing
11 Aug 2023
Next filing
02 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction QNCX Common Stock Options Exercise $49,792 +90,531 +20% $0.5500 539,442 16 Jan 2024 Direct
transaction QNCX Common Stock Options Exercise $140,999 +149,999 +28% $0.9400 689,441 16 Jan 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QNCX Employee Stock Option (right to buy) Options Exercise $0 -90,531 -44% $0.000000 115,860 16 Jan 2024 Common Stock 90,531 $0.5500 Direct F1
transaction QNCX Employee Stock Option (right to buy) Options Exercise $0 -149,999 -25% $0.000000 450,001 16 Jan 2024 Common Stock 149,999 $0.9400 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years.
F2 The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.